KR100213963B1 - Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis - Google Patents

Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis Download PDF

Info

Publication number
KR100213963B1
KR100213963B1 KR1019960703521A KR19960703521A KR100213963B1 KR 100213963 B1 KR100213963 B1 KR 100213963B1 KR 1019960703521 A KR1019960703521 A KR 1019960703521A KR 19960703521 A KR19960703521 A KR 19960703521A KR 100213963 B1 KR100213963 B1 KR 100213963B1
Authority
KR
South Korea
Prior art keywords
diaryl
osteoporosis
medicament
prevention
manufacture
Prior art date
Application number
KR1019960703521A
Other languages
English (en)
Inventor
M Labroo Virender
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of KR100213963B1 publication Critical patent/KR100213963B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1019960703521A 1993-12-30 1996-06-29 Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis KR100213963B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/175,899 US5389646A (en) 1993-12-30 1993-12-30 Methods for treatment and prevention of bone loss using 2,3-benzopyrans
PCT/US1994/014568 WO1995017892A1 (en) 1993-12-30 1994-12-14 Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis

Publications (1)

Publication Number Publication Date
KR100213963B1 true KR100213963B1 (en) 1999-08-02

Family

ID=22642125

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960703521A KR100213963B1 (en) 1993-12-30 1996-06-29 Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis

Country Status (11)

Country Link
US (1) US5389646A (ko)
KR (1) KR100213963B1 (ko)
CN (1) CN1142767A (ko)
AU (1) AU701411B2 (ko)
CA (1) CA2180178C (ko)
CZ (1) CZ192396A3 (ko)
FI (1) FI962685A (ko)
HU (1) HUT75705A (ko)
NO (1) NO962752L (ko)
RU (1) RU2166316C2 (ko)
WO (1) WO1995017892A1 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5637598A (en) * 1994-11-18 1997-06-10 Eli Lilly And Company Methods of inhibiting bone loss
JP2000514048A (ja) 1996-06-20 2000-10-24 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 薬理学的活性調製物を提供するための化合物および方法ならびにそれらの使用
US6043269A (en) * 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
WO2006032085A1 (en) 2004-09-21 2006-03-30 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
US8080675B2 (en) * 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US8703810B2 (en) 2010-06-10 2014-04-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
JP6013349B2 (ja) 2010-11-01 2016-10-25 メイ ファーマ, インク.Mei Pharma, Inc. 癌の処置のためのイソフラボノイド化合物および方法
AU2012351942B2 (en) 2011-12-14 2017-07-06 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
MX2017010002A (es) 2015-02-02 2018-02-09 Mei Pharma Inc Terapias de combinacion.
CN104926776B (zh) * 2015-07-06 2018-05-25 江南大学 4-苯甲酰亚甲基黄烷类衍生物的绿色合成方法
JP6855475B2 (ja) 2015-10-27 2021-04-07 スン プハルマ アドバンセド リサーチ カンパニー リミテド 新規ヘテロ環状抗エストロゲン剤
PE20221588A1 (es) 2019-07-22 2022-10-10 Sun Pharma Advanced Res Co Ltd Degradador selectivo del receptor de estrogeno

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1518002C3 (de) * 1965-01-02 1975-01-23 Merck Patent Gmbh, 6100 Darmstadt Isoflavane und Isoflavene und Verfahren zu Ihrer Herstellung sowie diese enthaltende Arzneimittel
US4210644A (en) * 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US4489056A (en) * 1982-06-30 1984-12-18 Merck & Co., Inc. Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance
US4644012A (en) * 1983-12-21 1987-02-17 Takeda Chemical Industries, Ltd. Treatment for osteoporosis
JPS60132976A (ja) * 1983-12-21 1985-07-16 Takeda Chem Ind Ltd 新規３−フエニル−４ｈ−１−ベンゾピラン−４−オン誘導体
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
JP3502403B2 (ja) * 1991-12-16 2004-03-02 アベンティス ファーマ株式会社 骨吸収抑制剤
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives

Also Published As

Publication number Publication date
US5389646A (en) 1995-02-14
CA2180178A1 (en) 1995-07-06
HU9601786D0 (en) 1996-09-30
RU2166316C2 (ru) 2001-05-10
AU1403995A (en) 1995-07-17
CN1142767A (zh) 1997-02-12
FI962685A (fi) 1996-08-28
CA2180178C (en) 2001-03-20
NO962752L (no) 1996-08-29
FI962685A0 (fi) 1996-06-28
CZ192396A3 (en) 1997-03-12
NO962752D0 (no) 1996-06-28
WO1995017892A1 (en) 1995-07-06
AU701411B2 (en) 1999-01-28
HUT75705A (en) 1997-05-28

Similar Documents

Publication Publication Date Title
HK1011926A1 (en) The use of bisphosphonates in bone surgery
GB9415125D0 (en) Surgical product and its use
IL127714A0 (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic depressive bipolar disorders
GB9419974D0 (en) Modular orthopedic brace
IL119894A (en) Use of thiazolidine in the preparation of a medicament for the treatment of osteoporosis
GB8900678D0 (en) Compositions for the prevention and medical treatment of parodonthopathy
KR100213963B1 (en) Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis
GB9312484D0 (en) Knee surgery
HK1022269A1 (en) Use of 1-hydroxy-2-pyridones in the manufacture of a medicament for treating skin infections
IL116142A0 (en) Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
AP9400676A0 (en) Process for the preparation of n-methyl-3-(1-methyl-4-piperidinyl)-1h-indole-5-ethanesulphonamid-e and physiologically acceptable salts thereof
HU9400290D0 (en) Pharmaceutical composition for preventing and treating retinal dieases
IL115224A0 (en) Preparations for use in the treatment of osteoporosis
HU9302183D0 (en) Medical preparatives for preventing and treating osteoporises after menopausa
HUP9802736A3 (en) Use of 1,4-dihydropyridine derivatives for the preparation of medicament for the prevention and therapy of atherosclerotic degradation in the arterial walls
GB9217124D0 (en) Medical treatment
IL109993A0 (en) Ipsapirone medicament formulation
HK44597A (en) Use of chlormethiazole in the manufacture of a medicament for the prevention and/or treatment of neurodegeneration
GB9408084D0 (en) Medical treatment
AU1176295A (en) Orthopedic casts
IL130103A0 (en) The use of a diarylalkane derivative in the manufacture of a medicament for treatment or prevention of pancreatitis
GB9321793D0 (en) Medical treatment
PL54844Y1 (en) Dental surgeon's syringe
EG19885A (en) Medicament for the treatment of hyperlipidaemia and/or atherosolerosis
GB9314074D0 (en) Orthopaedic splinting materials

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030512

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee